Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Neoplasms 1Urologic Neoplasms 1Kidney Neoplasms 1Kidney Diseases 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1

Interventions

pembrolizumab 16Carboplatin 10Paclitaxel 8Nivolumab 7Bevacizumab 6Gemcitabine 4Fulvestrant 4Cisplatin 4olaparib 3lenvatinib 3abemaciclib 3PM 01183 3Oxaliplatin 3Leucovorin 3Letrozole 3Docetaxel 3AZD5305 3tisotumab vedotin 2spartalizumab 2sarilumab 2sargramostim 2sacituzumab govitecan 2ribociclib 2palbociclib 2epacadostat 2enzalutamide 2dostarlimab 2cemiplimab 2anlotinib 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Endometrial Neoplasms × VMBP protocol × Clear all
NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

University of Alabama at Birmingham

Phase 1/2 Recruiting
37 enrolled
Gynecologic

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡